EHS
EHS

Oxtellar XR Gains Monotherapy Indication for Partial-Onset Seizures



The FDA has approved the supplemental New Drug Application for Oxtellar XR to include monotherapy use for the treatment of partial-onset seizures patients aged ≥6 years.

Source link

EHS
Back to top button